PharmaResearch (214450) is gaining attention from Daishin Securities for its profitability, financial stability, and overseas growth potential, as the company reports strong Q1 results and accelerates US market entry with an early Sephora launch. The firm's medical device exports are recovering in Q2, driven by reorders from Europe and new entries into the Middle East, while its cosmetics division gains traction in the US, Southeast Asia, and China. This signals opportunities for overseas buyers in the medical aesthetics supply chain, particularly for PDRN-based products and premium skincare lines.
Q1 Financial Performance and Profitability
PharmaResearch reported consolidated Q1 revenue of KRW 146.1 billion, up 25% year-on-year, and operating profit of KRW 573 billion, meeting market expectations. The company maintained a gross profit margin (GPM) of 77% and an operating profit margin (OPM) of 39%, reflecting strong profitability. Despite a 30% decline in spending by foreign visitors at domestic dermatology clinics, the domestic medical device segment performed well due to increased local demand and the addition of 400 new partner hospitals, including plastic surgery and primary care clinics.
Medical Device Export Recovery and Growth Drivers
In Q2, total revenue is expected to grow by a high single-digit percentage quarter-on-quarter, led by a 25% surge in medical device exports. European reorders have accelerated: after an initial KRW 2 billion shipment to VIVACY in January, reorders exceeded KRW 3 billion in April alone, indicating faster-than-expected inventory turnover. In the Middle East, initial shipments to Israel and Saudi Arabia have been completed, marking the start of meaningful revenue contributions.
Cosmetics Division: US Sephora Entry and Global Expansion
PharmaResearch's cosmetics division is gaining momentum. Domestically, SKU expansion at Olive Young and duty-free sales to foreign group tourists are driving growth. Internationally, the company has entered Shopee in Southeast Asia, China, and US Sephora stores. Notably, the US Sephora launch was completed in March, ahead of schedule, enabling the company to maintain premium pricing for its PDRN line and enhance brand recognition in the US market.
What Buyers Should Watch
Overseas importers and distributors should monitor PharmaResearch's expanding US retail presence via Sephora, which signals growing demand for PDRN-based medical aesthetics products. The company's strong financials and debt-free operations ensure supply reliability. Additionally, the upcoming launch of an invasive RF device (targeting November approval from the MFDS) and a synthetic collagen skin booster (targeting late 2027 approval) represent medium-to-long-term growth catalysts for clinic buyers and device distributors.
Regulatory and Channel Signals
PharmaResearch's early Sephora entry in the US and rapid European reorder cycles indicate strong channel acceptance and regulatory compliance. The company's ability to secure new hospital partnerships (400 new accounts in Q1) and expand into the Middle East suggests robust distribution capabilities. Buyers should note that the company maintains a target multiple of 28.6x forward P/E, reflecting a 30% discount to Galderma's peer average due to its early European expansion stage, which may influence pricing and partnership terms.
Source: Read the original report | Published: June 02, 2026